MET and cancer: Anti-c-Met monoclonal antibodies (mAb) were rapidly developed as nuclear imaging agents for treating various human cancers [19–21], but poor tumor penetration due to the big size of molecules, as well as liver or bone marrow toxicity, has limited applications [22].